Sandra Van Lint

2.1k total citations
30 papers, 1.6k citations indexed

About

Sandra Van Lint is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Sandra Van Lint has authored 30 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 15 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Sandra Van Lint's work include Immunotherapy and Immune Responses (22 papers), RNA Interference and Gene Delivery (12 papers) and CAR-T cell therapy research (11 papers). Sandra Van Lint is often cited by papers focused on Immunotherapy and Immune Responses (22 papers), RNA Interference and Gene Delivery (12 papers) and CAR-T cell therapy research (11 papers). Sandra Van Lint collaborates with scholars based in Belgium, France and Germany. Sandra Van Lint's co-authors include Karine Breckpot, Kris Thielemans, Carlo Heirman, Jan Tavernier, Stefaan De Koker, Sarah Maenhout, Lien Van Hoecke, Cleo Goyvaerts, Heleen Dewitte and Ine Lentacker and has published in prestigious journals such as Advanced Materials, Nature Communications and Cancer Research.

In The Last Decade

Sandra Van Lint

30 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Van Lint Belgium 23 1.1k 871 592 248 188 30 1.6k
Joyce Chen United States 9 1.0k 0.9× 610 0.7× 924 1.6× 328 1.3× 270 1.4× 20 2.0k
Franziska Blaeschke Germany 18 449 0.4× 658 0.8× 832 1.4× 288 1.2× 165 0.9× 33 1.4k
Cleo Goyvaerts Belgium 23 821 0.8× 646 0.7× 648 1.1× 175 0.7× 86 0.5× 48 1.4k
Murillo Silva United States 10 599 0.6× 389 0.4× 341 0.6× 100 0.4× 159 0.8× 14 1.0k
Yoshihiro Miyahara Japan 21 1.3k 1.2× 488 0.6× 839 1.4× 118 0.5× 180 1.0× 61 1.9k
Mathias Oelke United States 24 1.4k 1.3× 451 0.5× 947 1.6× 133 0.5× 240 1.3× 63 2.0k
Angel Varela‐Rohena United States 9 835 0.8× 381 0.4× 1.1k 1.9× 395 1.6× 251 1.3× 12 1.6k
Amy Wesa United States 21 1.3k 1.3× 494 0.6× 711 1.2× 189 0.8× 92 0.5× 35 1.9k
Eva Lion Belgium 29 1.9k 1.8× 731 0.8× 1.3k 2.3× 174 0.7× 215 1.1× 64 2.6k
Eryn Blass United States 9 797 0.8× 432 0.5× 397 0.7× 76 0.3× 126 0.7× 12 1.1k

Countries citing papers authored by Sandra Van Lint

Since Specialization
Citations

This map shows the geographic impact of Sandra Van Lint's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Van Lint with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Van Lint more than expected).

Fields of papers citing papers by Sandra Van Lint

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Van Lint. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Van Lint. The network helps show where Sandra Van Lint may publish in the future.

Co-authorship network of co-authors of Sandra Van Lint

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Van Lint. A scholar is included among the top collaborators of Sandra Van Lint based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Van Lint. Sandra Van Lint is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lint, Sandra Van, Alexander Van Parys, Niels Vandamme, et al.. (2023). A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state. Molecular Cancer. 22(1). 191–191. 6 indexed citations
2.
Lint, Sandra Van, Elianne Burg, Stéphane Plaisance, et al.. (2021). Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication. Journal for ImmunoTherapy of Cancer. 9(11). e003293–e003293. 15 indexed citations
3.
Hoecke, Lien Van, Rein Verbeke, Heleen Dewitte, et al.. (2021). mRNA in cancer immunotherapy: beyond a source of antigen. Molecular Cancer. 20(1). 48–48. 54 indexed citations
4.
Cauwels, Anje, Sandra Van Lint, Elke Rogge, et al.. (2021). Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE. Scientific Reports. 11(1). 21575–21575. 8 indexed citations
5.
Hoecke, Lien Van, Elianne Burg, Sandra Van Lint, et al.. (2020). Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant. npj Vaccines. 5(1). 64–64. 23 indexed citations
6.
Hoecke, Lien Van, Kenny Roose, Marlies Ballegeer, et al.. (2020). The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration. Molecular Therapy — Nucleic Acids. 22. 373–381. 35 indexed citations
7.
Zabeau, Lennart, Joris Wauman, Julie Dam, et al.. (2019). A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions. Cellular and Molecular Life Sciences. 76(6). 1201–1214. 15 indexed citations
8.
Cauwels, Anje, Sandra Van Lint, Dominiek Catteeuw, et al.. (2018). Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. Journal of Autoimmunity. 97. 70–76. 20 indexed citations
9.
Hoecke, Lien Van, Sandra Van Lint, Kenny Roose, et al.. (2018). Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nature Communications. 9(1). 3417–3417. 118 indexed citations
10.
Cauwels, Anje, Sandra Van Lint, Franciane Paul, et al.. (2017). Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Research. 78(2). 463–474. 75 indexed citations
11.
Lint, Sandra Van, Dries Renmans, Katrijn Broos, et al.. (2016). Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells. Cancer Immunology Research. 4(2). 146–156. 101 indexed citations
12.
Beuckelaer, Ans De, Charlotte Pollard, Sandra Van Lint, et al.. (2016). Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses. Molecular Therapy. 24(11). 2012–2020. 99 indexed citations
13.
Jeught, Kevin Van der, Sandra Van Lint, Kris Thielemans, & Karine Breckpot. (2015). Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. OncoImmunology. 4(5). e1005504–e1005504. 9 indexed citations
14.
Dewitte, Heleen, Sandra Van Lint, Carlo Heirman, et al.. (2014). The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy. Journal of Controlled Release. 194. 28–36. 105 indexed citations
15.
Lint, Sandra Van, Dries Renmans, Katrijn Broos, et al.. (2014). The ReNAissanCe of mRNA-based cancer therapy. Expert Review of Vaccines. 14(2). 235–251. 68 indexed citations
16.
Lint, Sandra Van, Sofie Wilgenhof, Carlo Heirman, et al.. (2014). Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunology Immunotherapy. 63(9). 959–967. 75 indexed citations
17.
Benteyn, Daphné, Sébastien Anguille, Sandra Van Lint, et al.. (2013). Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Molecular Therapy — Nucleic Acids. 2. e134–e134. 40 indexed citations
18.
Lint, Sandra Van, Carlo Heirman, Kris Thielemans, & Karine Breckpot. (2013). mRNA. Human Vaccines & Immunotherapeutics. 9(2). 265–274. 48 indexed citations
19.
Emeagi, Perpetua U., Sandra Van Lint, Cleo Goyvaerts, et al.. (2012). Proinflammatory Characteristics of SMAC/DIABLO-Induced Cell Death in Antitumor Therapy. Cancer Research. 72(6). 1342–1352. 26 indexed citations
20.
Bos, Tomas, Elke De Bruyne, Sandra Van Lint, Carlo Heirman, & Karin Vanderkerken. (2010). Large double copy vectors are functional but show a size-dependent decline in transduction efficiency. Journal of Biotechnology. 150(1). 37–40. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joyce Chen Breakdown of academic impact, for papers by Franziska Blaeschke Breakdown of academic impact, for papers by Cleo Goyvaerts Breakdown of academic impact, for papers by Murillo Silva Breakdown of academic impact, for papers by Yoshihiro Miyahara Breakdown of academic impact, for papers by Mathias Oelke Breakdown of academic impact, for papers by Angel Varela‐Rohena Breakdown of academic impact, for papers by Amy Wesa Breakdown of academic impact, for papers by Eva Lion Breakdown of academic impact, for papers by Eryn Blass
Rankless by CCL
2026